Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1

Status

Recruiting 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 2NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 473Neoplasms 290Breast Neoplasms 277Colorectal Neoplasms 223Neoplasm Metastasis 187Prostatic Neoplasms 168Ovarian Neoplasms 163Lung Neoplasms 154Multiple Myeloma 152Recurrence 132Melanoma 116Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 104Endometrial Neoplasms 98Stomach Neoplasms 97Leukemia, Myeloid, Acute 95Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 81Triple Negative Breast Neoplasms 80Carcinoma, Renal Cell 79Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 63Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 55Head and Neck Neoplasms 53

Interventions

enzalutamide 2abiraterone 2darolutamide 1Prednisolone 1Docetaxel 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Bulbo-Spinal Atrophy, X-Linked × 90 days × Clear all
NCT07190300 2026-06-03

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting
181 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Corcept Therapeutics

Phase 1/2 Terminated
39 enrolled 43 charts
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06764485 2026-05-06

rechARge

Celgene

Phase 3 Recruiting
960 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07336446 2026-05-01

ANDROMEDA

AstraZeneca

Phase 1/2 Recruiting
300 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡